News

Research with Impact-Dr. Gail Gauvreau

  • February 18, 2016
  • News

A series of articles has been created by HHS Research which shine the spotlight on studies published in 2014 with an HHS Researcher as lead author. Each piece features a study published in a journal with an Impact Factor greater than 10 and provides information about the author and about the research they lead. If their work strikes a cord with you, Tweet us at @HamHealthSc and include hashtag: HHSResearch

Dr. Gail Gauvreau is an Associate Professor at McMaster University. She completed her BSc/MSc, at the University of Guelph, her PhD at McMaster University and a Postdoctoral Fellowship at the Johns Hopkins University. Her research interests include the mechanisms of allergic inflammation, novel therapeutic targets for asthma and COPD, airway inflammation in asthma and COPD, and cysteinyl leukotrienes and cysLT receptors.  

Publication:

Gauvreau, G., O’ Byrne, P. (2014). Effects of an Anti-TSLP Antibody on allergen-induced asthmatic responses. New England Journal of Medicine, 370, 2102-2110.

Background of study: Thymic stromal lymphopoietin (TSLP) is an epithelial-cell-derived cytokine that may be important in initiating allergic inflammation. AMG 157 is a human anti-TSLP monoclonal immunoglobulin G2λ that binds human TSLP and prevents receptor interaction.

Conclusions: Treatment with AMG 157 reduced allergen-induced bronchoconstriction and indexes of airway inflammation before and after allergen challenge. These findings are consistent with a key role for TSLP in allergen-induced airway responses and persistent airway inflammation in patients with allergic asthma. Whether anti-TSLP therapeutics will have clinical, value cannot be determined from these data.